References
- KasperSSacherJKleinNDifferences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopramInt Clin Psychopharmacol200924311912519367152
- JacquotCDavidDJGardierAMSánchezCEscitalopram and citalopram: the unexpected role of the R-enantiomerEncephale2007332179187 French.17675913
- BaldwinDSReinesEHGuitonCWeillerEEscitalopram therapy for major depression and anxiety disordersAnn Pharmacother200741101583159217848424
- RabinowitzIBaruchYBarakYHigh-dose escitalopram for the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol2008231495318090508
- WadeAGCrawfordGMYellowleesAEfficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot studyBMC Psychiatry2011114221410960
- WaringWSClinical use of antidepressant therapy and associated cardiovascular riskDrug Healthc Patient Saf201249310122936860
- Garnock-JonesKPMcCormackPLEscitalopram: a review of its use in the management of major depressive disorder in adultsCNS Drugs201024976979620806989
- BaldwinDSCooperJAHuusomAKHindmarchIA double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorderInt Clin Psychopharmacol200621315916916528138
- KasperSLemmingOMde SwartHEscitalopram in the long-term treatment of major depressive disorder in elderly patientsNeuropsychobiology200654315215917230032
- American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders. Text Revision4th ed.Washington DCAmerican Psychiatric Association2000
- FirstMBSpitzerRGibbonMWilliamsJBWStructured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P)New YorkBiometrics Research, New York State Psychiatric Institute2002
- FirstMBGibbonMSpitzerRLWilliamsJBWBenjaminLSStructured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II)Washington DCAmerican Psychiatric Press1997
- HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
- HamiltonMThe assessment of anxiety states by ratingBr J Med Psychol1959321505513638508
- MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
- GuyWClinical global impressionsECDEU Assessment Manual for Psychopharmacology RevisedRockville, MDUS Department of Health and Human Services1976218222
- HowlandRHA question about the potential cardiac toxicity of escitalopramJ Psychosoc Nurs Ment Health Serv20125041720
- HanashJAHansenBHHansenJFNielsenOWRasmussenABirket-SmithMCardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with coronary Artery Disease (DECARD) trialJ Cardiovasc Pharmacol201260439740522820898
- CadieuxRJPractical management of treatment-resistant depressionAm Fam Physician1998589205920629861879
- RochaFLFuzikawaCRieraRHaraCCombination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysisJ Clin Psychopharmacol201232227828122367652
- RushAJTrivediMHStewartJWCombining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized studyAm J Psychiatry2011168768970121536692
- ReisMChermáMDCarlssonBBengtssonFTask Force for TDM of Escitalopram in SwedenTherapeutic drug monitoring of escitalopram in an outpatient settingTher Drug Monit200729675876618043473
- HöschlCSvestkaJEscitalopram for the treatment of major depression and anxiety disordersExpert Rev Neurother20088453755218416657